PH-109

Vehicle (PBS), a chemically-identical non-targeting control (NTC) INTASYL or PH-109 at two dose concentrations (0.5 mg; 2 mg) were administered IT; doxorubicin chemotherapy (5 mg/kg) was administered intraperitoneally on Days 1, 7, 13. This, combined with these data in a clinically relevant orthotopic mouse model of metastatic breast cancer, could support accelerated clinical investigation of PH-109 as an anticancer therapeutic. Ethics Approval Animal studies were performed at Pharma Models LLC, Marlborough, MA 01752, under standard protocol approved by their IACUC.